Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
2(40%)
Results Posted
67%(2 trials)

Phase Distribution

Ph phase_4
1
20%
Ph phase_2
1
20%
Ph phase_3
2
40%
Ph not_applicable
1
20%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
2(40.0%)
Phase 4Post-market surveillance
1(20.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(3)

Detailed Status

Completed3
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (20.0%)
Phase 32 (40.0%)
Phase 41 (20.0%)
N/A1 (20.0%)

Trials by Status

completed360%
recruiting240%

Recent Activity

2 active trials
Showing 5 of 5
recruitingnot_applicable

Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans

NCT07506369
completedphase_4

Preemptive IV Ibuprofen for Neurocognitive Recovery and Analgesic Needs After Inguinal Hernia Surgery

NCT07424001
recruitingphase_3

Certolizumab in Recurrent Implantation Failure (RIF)

NCT05930613
completedphase_2

Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India

NCT01550289
completedphase_3

Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America

NCT01374516

Clinical Trials (5)

Showing 5 of 5 trials
NCT07506369Not Applicable

Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans

Recruiting
NCT07424001Phase 4

Preemptive IV Ibuprofen for Neurocognitive Recovery and Analgesic Needs After Inguinal Hernia Surgery

Completed
NCT05930613Phase 3

Certolizumab in Recurrent Implantation Failure (RIF)

Recruiting
NCT01550289Phase 2

Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India

Completed
NCT01374516Phase 3

Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5